Lead clinical candidate CTX-187 is a novel antimicrobial immunotherapy developed to treat clinically-prevalent and multi-drug resistant Gram-negative bacterial infections -- Qualified Infectious ...

Drugmakers must focus on developing new antibiotics to fight hospital “superbugs” including meningitis and other infections that can resist last-line treatments, the World Health Organization (WHO) ...

Multidrug-resistant gram-negative infections (MDRGNIs) are an emerging and deadly threat worldwide. Some of these infections are now resistant to nearly all antibiotics, and very few treatment options ...

Infections caused by gram-negative bacteria have features that are of particular concern. These organisms are highly efficient at up-regulating or acquiring genes that code for mechanisms of ...

Antibiotic resistance among Gram‐negative bacteria represents one of the most pressing challenges in modern medicine. These pathogens have evolved multiple mechanisms to evade the effects of ...

Please provide your email address to receive an email when new articles are posted on . Gram-negative bacteria comprise most of the CDC and WHO’s lists of critical and urgent antibiotic-resistant ...

Hospital uptake of newer antibiotics to treat multidrug-resistant gram-negative bacteria was low over a 5-year period, according to a retrospective cohort study. Fully 41.5% of episodes of ...

Gram-negative meningitis is a form of meningitis. The term gram-negative refers to a way of differentiating bacteria. This type of bacteria is typically resistant to drugs and most available ...

A mineral-hogging fungus can “bully” bacteria into becoming more antibiotic resistant, according to new work published June 20 in the journal PLOS Biology by Fred Hutch Cancer Center scientists. The ...

Based on the Company's Alphamer® platform, the compound is designed to target serious Gram-negative bacterial infections in the lung, expanding therapeutic options for the most vulnerable patients.

Lead clinical candidate CTX-187 is a novel antimicrobial immunotherapy developed to treat clinically-prevalent and multi-drug resistant Gram-negative bacterial infections Qualified Infectious Disease ...